- Home
- PINE vs ITOS Comparison
PINE vs ITOS Comparison
Compare PINE & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- ITOS
- Stock Information
- Founded
- PINE 2019
- ITOS 2011
- Country
- PINE United States
- ITOS United States
- Employees
- PINE N/A
- ITOS N/A
- Industry
- PINE Real Estate Investment Trusts
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PINE Real Estate
- ITOS Health Care
- Exchange
- PINE Nasdaq
- ITOS Nasdaq
- Market Cap
- PINE 239.5M
- ITOS 283.9M
- IPO Year
- PINE 2019
- ITOS 2020
- Fundamental
- Price
- PINE $17.21
- ITOS $7.54
- Analyst Decision
- PINE Strong Buy
- ITOS Strong Buy
- Analyst Count
- PINE 9
- ITOS 3
- Target Price
- PINE $19.39
- ITOS $25.33
- AVG Volume (30 Days)
- PINE 93.6K
- ITOS 448.3K
- Earning Date
- PINE 02-06-2025
- ITOS 11-12-2024
- Dividend Yield
- PINE 6.43%
- ITOS N/A
- EPS Growth
- PINE N/A
- ITOS N/A
- EPS
- PINE 0.23
- ITOS N/A
- Revenue
- PINE $50,017,000.00
- ITOS $35,000,000.00
- Revenue This Year
- PINE N/A
- ITOS $271.18
- Revenue Next Year
- PINE $6.76
- ITOS N/A
- P/E Ratio
- PINE $75.37
- ITOS N/A
- Revenue Growth
- PINE 9.55
- ITOS N/A
- 52 Week Low
- PINE $14.33
- ITOS $7.44
- 52 Week High
- PINE $19.42
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- PINE 39.08
- ITOS 34.10
- Support Level
- PINE $17.04
- ITOS $7.44
- Resistance Level
- PINE $17.37
- ITOS $7.96
- Average True Range (ATR)
- PINE 0.28
- ITOS 0.34
- MACD
- PINE -0.06
- ITOS -0.02
- Stochastic Oscillator
- PINE 17.82
- ITOS 9.97
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate company. It owns and operates a portfolio of single-tenant commercial properties. The company's portfolio is comprised of single-tenant retail and office properties located in or in close proximity to MSAs, growth markets and other markets in the United States. Their portfolio consists of One thirty eight net leased properties located in Hundred and four markets in thirty five states. The majority of the firm's revenue includes rental revenue derived from the ownership and leasing of property.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.